Trials / Terminated
TerminatedNCT00907764
Stress Echocardiography Study With Regadenoson
An Open-Label, Parallel-Group, Exploratory Study to Evaluate the Efficacy and Safety of 400 ug Regadenoson Bolus for Pharmacological Stress Echocardiography
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Regadenoson is approved in the US under the brand name Lexiscan for myocardial perfusion imaging. This study will test whether regadenoson is an appropriate stress agent for stress echocardiography.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | regadenoson | 400 ug, IV |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2010-04-01
- Completion
- 2010-04-01
- First posted
- 2009-05-25
- Last updated
- 2014-01-23
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00907764. Inclusion in this directory is not an endorsement.